Bio-Synthesis, Inc.

Lewisville, TX Doing business as Dnaexam

UEI
MWJBT69QFLH4
CAGE
1EKY7
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Subchapter S Corporation
  • Hispanic American Owned
  • Minority Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
800 Mario Ct, Lewisville, TX 75057, USA
Website
biosyn.com
Founded
1984
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $10,585
FY2024 $0
FY2023 $10,950

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Similar vendors

About the company

Bio-Synthesis, Inc., operating under the trade name Dnaexam, is a Hispanic American-owned corporate entity registered in SAM.gov since 2002, specializing in advanced biological research materials and custom synthesis services. Located in Lewisville, Texas, the company is structured as a for-profit, Subchapter S Corporation that manufactures scientific goods with a focus on specialized molecular and genetic research products. As a manufacturer of goods, Bio-Synthesis, Inc. demonstrates expertise in producing complex biological materials for federal research institutions, with a particular emphasis on peptide, RNA, and nucleic acid synthesis.

The company has secured multiple federal contract awards from prominent health-related research agencies, including the National Heart Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, and National Institute on Drug Abuse. Their federal contract awards reveal a specialized capability in producing custom research materials, such as stapled NIX-derived peptides with derivatized N-termini, custom RNA synthesis, and RNA oligos specifically supporting COVID-19 research. The contract awards, ranging from $10,585 to $28,135, are structured as purchase orders with no specific set-aside designations. These contracts demonstrate Bio-Synthesis, Inc.'s technical capacity to deliver precise, high-quality molecular research materials that support critical scientific investigations across various biomedical research domains, with a notable recent contribution to pandemic-related research efforts.

SBA capabilities narrative

Core Services

Oligonucleotide synthesis

Peptide synthesis

Antibody production

Bio-conjugation services

Organic synthesis

Molecular Biology Services (Cloning, Protein Expression and SNP Genotyping)

Analytical services (MS, HPLC, GC, AAA, Sequencing, Etc.)

Complex oligonucleotide synthesis and modifications

o Complex oligonucleotide constructs with multiple labels

o Chemical DNA (up to 300 bases), RNA (up to 200 bases)

o Ultra long RNA Transcripts >3000 nucleotides

o Multi-gram DNA and RNA oligomer production

o Oligonucleotide-biomolecule or small molecule conjugates (siRNA-peptide conjugates, DNA-peptides, RNA-peptide conjugates)

o Exclusive provider of a novel nucleic acid analog, namely BNA (bridged nucleic acid)

Complex peptide synthesis and modifications

o Custom peptide synthesis up to 150 amino acids

o Large volume peptide manufacturing facility

o Large scale peptide production

o Peptide-biomolecule or small molecule conjugates

Antibody and protein engineering

Quick answers

Is Bio-Synthesis, Inc. registered in SAM.gov?

Yes. Bio-Synthesis, Inc.'s SAM.gov registration is active through September 18, 2027.

What is Bio-Synthesis, Inc.'s CAGE code?

Bio-Synthesis, Inc.'s CAGE code is 1EKY7, and its Unique Entity ID (UEI) is MWJBT69QFLH4.

How much has Bio-Synthesis, Inc. received in federal contracts?

Federal contracts obligated $10,585 to Bio-Synthesis, Inc. in fiscal year 2025 and $21,535 in fiscal years 2023 through 2027.

What is Bio-Synthesis, Inc.'s most recent federal award?

Bio-Synthesis, Inc.'s most recent federal contract award is [25-008602] the laboratory of structural biophysics requires the stapled NIX-derived peptides with derivatized… (75N92025P00180), from National Heart Lung and Blood Institute (NIH), on April 24, 2025.

On GovTribe

See Bio-Synthesis, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe